Evidence map›Paper›PMID 38836196›Full record

ArticleJAC-antimicrobial resistance2024

Evaluating the antimicrobial efficacy of ceftriaxone regimens: 1 g twice daily versus 2 g once daily in a murine model of

Hideo Kato, Mao Hagihara, Shun-Ichi Hiramatsu, Hiroyuki Suematsu, Naoya Nishiyama, Nobuhiro Asai, Hiroshige Mikamo, Kazuko Yamamoto, Takuya Iwamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Antibiotic therapy for bacterial pneumonia.Journal of pharmaceutical health care and sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hideo KatoDepartment of Pharmacy, Mie University Hospital, Mie, Japan.ORCID https://orcid.org/0000-0002-5272-9560
Mao HagiharaDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Shun-Ichi HiramatsuDepartment of Pharmacy, Mie University Hospital, Mie, Japan.
Hiroyuki SuematsuDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Naoya NishiyamaDepartment of Infection Control, University of the Ryukyus Hospital, Okinawa, Japan.
Nobuhiro AsaiDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Hiroshige MikamoDepartment of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan.
Kazuko YamamotoDepartment of Infection Control, University of the Ryukyus Hospital, Okinawa, Japan.
Takuya IwamotoDepartment of Pharmacy, Mie University Hospital, Mie, Japan.ORCID https://orcid.org/0000-0002-6445-4410

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ceftriaxone is administered in regimens of either 2 g once-daily or 1 g twice-daily for the treatment of pneumonia caused by Objectives: To assess the antimicrobial efficacy of these two ceftriaxone regimens against Methods: The study employed three Results: The human-simulated 2 g once-daily regimen of ceftriaxone exhibited significantly higher antimicrobial activity against Conclusion: 2 g once-daily regimen of ceftriaxone is more effective for treating pneumonia caused by

Identifiers

PMID38836196
PMCPMC11148390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.